CYDY · CytoDyn Inc.
$0.20
0.00 (-2.01%)
At close · Jul 28
Going-concern doubt
— flagged Apr 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, including the various matters discussed in Note 10, *Commitments and Contingencies*, raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Apr 8, 2026
Market Cap
$266.38M
Shares
1.37B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.20
Open$0.20
Day$0.19–0.20
52W$0.19–0.40
Avg vol 30d2.0M
Short int36.3M · 2.7% float · 9.5d
Short vol69%
DataJan 2020–Jul 2026
Filing10-Q · Apr 8
Up next
FQ1-27 quarter ends
~Aug 31, 2026
Est
filed Apr 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−27%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−22%
trailing
YTD return
−30%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
5 of 9 funds reported for Jun 30 · net -170.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.66% of float · ▲ +0.0% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$-8.9M
Balance sheet
$9.6M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
9.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Death cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
5 of 9 funds reported for Jun 30 · net -170.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.66% of float · ▲ +0.0% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 4%
52-wk high $0
vs 200-day avg -29%
vs 50-day avg -27%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYDY
this stock
CytoDyn Inc.
|
$266.38M | -30.4% | -100.0% | — | 2.7% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
6
- % held
- 0.0%
- Reported
- 5 of 9
- Top holder
- Diversified Trust Co
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYDY | -2.5% | -22.0% | -22.0% | -18.8% | -30.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.5% | -22.0% | -29.4% | -18.0% | -39.0% |